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Abstract
Background: Some probiotics have shown efficacy for patients with irritable bowel syndrome (IBS). Lactobacillus
(L.) plantarum MF1298 was found to have the best in vitro probiotic properties of 22 strains of lactobacilli. The aim
of this study was to investigate the symptomatic effect of L. plantarum MF1298 in subjects with IBS. Primary
outcome was treatment preference and secondary outcomes were number of weeks with satisfactory relief of
symptoms and IBS sum score.
Methods: The design was a randomised double blind placebo-controlled crossover trial. 16 subjects with IBS
underwent two three-week periods of daily intake of one capsule of 1010 CFU L. plantarum MF 1298 or placebo
separated by a four-week washout period.
Results: Thirteen participants (81%; 95% CI 57% to 93%; P = 0.012) preferred placebo to L. plantarum MF1298
treatment. The mean (SD) number of weeks with satisfactory relief of symptoms in the periods with L. plantarum
MF1298 and placebo were 0.50 (0.89) and 1.44 (1.26), respectively (P = 0.006). IBS sum score was 6.44 (1.81) in the
period with L. plantarum MF1298 treatment compared with 5.35 (1.77) in the period with placebo (P = 0.010). With
a clinically significant difference in the IBS sum score of 2 in disfavour of active treatment, the number needed to
harm was 3.7, 95% CI 2.3 to 10.9.
Conclusions: This trial shows for the first time an unfavourable effect on symptoms in subjects with IBS after
intake of a potential probiotic.
The trial registration number: Clinical trials NCT00355810.
Background
Irritable bowel syndrome (IBS) is the most frequent
functional gastrointestinal disorder, with a prevalence of
5-11% in most countries [1]. The workload generated by
IBS is considerable and constitutes approximately one-
third of all visits to gastroenterologists [2]. It is a biopsy-
chosocial disorder that requires a multifactorial
approach [3]. No proper treatment is available.
The human gut contains over 1000 different bacterial
species and an indeterminate number of strains of
which a minority of the strains is cultivable [4] Probio-
tics are defined as “live microorganisms which when
administered in adequate amounts confer a health bene-
fit on the host” [5]. Some studies have shown beneficial
effect of probiotics in IBS [6]. Lactobacillus (L.) plan-
tarum 299v reduced flatulence and abdominal pain in
patients with IBS [7]. L. plantarum MF1298 was found
to have the best in vitro probiotic properties of 22
strains of lactobacilli isolated from fermented food pro-
ducts. This strain was confirmed to adhere to the
human colon adenoma cell line CaCo2, to strengthen
transepithelial resistance of a CaCo2 cell layer and to
increase production of certain tight junction proteins, to
have antimicrobial activity against potential pathogens,
and to survive passage through the human gastrointest-
inal tract [8-10]. L. plantarum MF1298 was therefore
proposed as a potential candidate probiotic strain.
The aims of this randomised placebo-controlled cross-
over trial were to study the effect of L. plantarum
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MF1298 on treatment preference, satisfactory relief of
symptoms and symptoms in subjects with IBS.
Methods
Participants
Participants were recruited from a hospital-based gastro-
enterology outpatient clinic and a private gastroentero-
logical practice. Subjects 18 to 75 years of age with IBS
according to the Roma II criteria and symptoms the last
three months were eligible for inclusion. All subjects
had had a sigmoidoscopy or colonoscopy performed
within the last five years to exclude organic disease.
Other tests to confirm the diagnosis were performed at
the physicians’ discretion. Pregnant and breast-feeding
women and subjects with major psychiatric, mental or
behavioural disorders, coexisting gastrointestinal and
other disorders that might influence the symptoms, or
poor knowledge of language were excluded, as were
those who had used probiotics more than once a week
in the previous three weeks or antibiotics or laxatives in
the previous five weeks. The study was made in accor-
dance with the Helsinki Declaration and all participants
gave written informed consent to participation before
enrolment. The Regional medical research ethics com-
mittee, Central Norway approved the study protocol.
Study design
The study was a randomised double blind, placebo-con-
trolled, crossover trial with a one-week run-in period
followed by randomisation and two three-week treat-
ment periods separated by a four-week washout period.
Participants with satisfactory relief of symptoms in the
run-in period were excluded from further participation.
IBS symptoms were recorded on diary cards every eve-
ning during the run-in period, during the last week of
the washout period, and the last week of the two treat-
ment periods. Satisfactory relief of symptoms was
recorded on diary cards at the end of the run-in and
washout periods and at the end of each week during the
treatment periods. At the end of the study, the partici-
pants recorded treatment preference for one of the
treatment periods. Faecal samples were collected at the
end of the run-in, washout period, and the two treat-
ment periods. All data were collected at the hospital
based gastroenterology outpatient clinic at Innlandet
Hospital Trust, Gjøvik.
The computer-based randomisation was performed at
the Unit for Applied Clinical Research, Norwegian Univer-
sity of Science and Technology, Trondheim, Norway. Faun
Pharma, Norway, provided packed and numbered contain-
ers with the capsules containing 1010 CFU live, freeze-
dried L. plantarum MF 1298 or placebo according to the
randomisation list. The capsules were confirmed to con-
tain the correct number of pure L. plantarum MF1298 by
classical and genetic methods, and were checked for the
presence of common pathogens. The capsules looked
identical and were prescribed to be taken once daily with
liquid. The participants and health care providers were
blinded until data entry was complete.
Assessments
The participants were asked about treatment preference
(the period with least symptoms) at the last visit, and
about satisfactory relief of symptoms (yes/no) at the end
of the run-in and washout periods and at the end of each
week during the treatment periods. Seven gastrointestinal
symptoms were recorded. Abdominal pain/discomfort,
urgency and bloating were recorded as none, mild, mod-
erate, or severe (score 0-3); stool frequency as number of
stools per day; stool consistency according to Bristol
stool scale form (score 1-7); and straining and incomplete
bowel movement as yes/no (score: 1 or 0) [11]. An IBS
sum score (score 0-15) was calculated as the sum of
these seven scores after “normalisation” of stool fre-
quency and consistency to achieve low scores for normal
bowel habits. The “normalisation” was performed as fol-
lows: Stool frequency: 0 stool/day = 1; 1-3 stools/day = 0;
4-5 stools/day = 1; ≥ 6 stools/day = 2. Stool consistency:
Bristol stool scale 3-5 = 0; Bristol stool scale 2 and 6 = 1;
Bristol stool scale 1 and 7 = 2. A diarrhoea score was cal-
culated as the sum of the “none normalised” scores of
stool frequency and stool consistency. Assessment of
compliance was based on returned capsules.
Faecal samples, frozen in Carey Blair medium (Oxoid
Ltd, Basingstoke, Hampshire, UK), were analyzed for
detection of L. plantarum by real-time PCR using 50
cycles. Primers: 5’-TGG ACC GCA TGG TCC GAG-3’
(F) and 5’-GTG AGC CGT TAC CCC ACC AT-3’ (R),
and the Taqman probe 5’-TCC CGC GGC GTA TTA-
3’, targeting a specific L. plantarum region of the con-
served 16S rDNA sequence, were used in the analysis.
Verification of specificity and control of efficiency of the
primer-probe pair were performed according to stan-
dard procedures, and will be documented elsewhere
(Rudi et al., manuscript in preparation).
Outcomes
The primary outcome measure was treatment prefer-
ence. Secondary outcomes were the number of weeks
with satisfactory relief of symptoms and the IBS sum
score. All comparisons were between treatment with L.
plantarum MF1298 and placebo. Presence of L. plan-
tarum MF1298 was assessed by analysis of faeces as
described above. Adverse events were noted.
Statistical methods
The sample size calculation was based on the treatment
preference (the proportion of participants preferring one
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treatment period to the other). Nineteen participants
were required to reveal a treatment preference of 80%
compared with the null hypothesis value of 50%, with
80% power at a two-sided significance level of 5%.
Changes within and between groups were compared
with paired t test and independent t test, respectively.
The confidence interval and P value for treatment pre-
ference were calculated with the Wilson (score) method.
The difference between treatment periods as regards
number of subjects with satisfactory relief of symptoms
for zero, one, two and three weeks was tested with the
marginal homogeneity test for matched ordinal vari-
ables. The number needed to harm was calculated by
the method described by Walter, with a difference ≥ 2
in the IBS sum score between L. plantarum MF1298
and placebo regarded as clinically significant [12]. Two-
sided P values < 0.05 were considered statistically signif-
icant, and the 95% confidence interval (CI) was calcu-
lated for the main outcomes. Modified intention-to-treat
analysis was performed. All results are given as mean
(SD) unless otherwise indicated.
Results
Twenty-eight participants were included between Janu-
ary and April 2006. Figure 1 shows the flow of partici-
pants through the trial. Sixteen participants (five males
and eleven females) with a mean age of 50 (11) years
and BMI 24 (3) kg/m2 were available for the modified
intension-to-treat analysis; one had constipation-predo-
minant, nine alternating, and six diarrhoea-predominant
IBS. The IBS sum score at run-in was 6.21 (1.63), and
the duration of symptoms was 31 (17) years. Four parti-
cipants with protocol violations were included in the
modified intention-to-treat analyses; two had inade-
quately completed diary cards (three and five days,
respectively), one used an antibiotic during the active
period, and one received supplementary treatment for
IBS in the placebo period.
Thirteen participants (81%; CI 57% to 93%; P = 0.012)
preferred placebo to L. plantarum MF1298 treatment.
The number of weeks with satisfactory relief of symptoms
was statistically significantly higher in the placebo period
compared with the L. plantarum MF1298 period (Table 1
and 2) and the IBS sum score and the score for diarrhoea
were significantly higher in the period of L. plantarum
MF1298 treatment than with placebo (Table1). The sub-
classes of IBS (diarrhoea predominant, constipation predo-
minant, and alternating) showed the same tendency for
higher IBS sum scores in the period with L. plantarum
MF1298 compared with placebo (data not shown). Figure
2 shows the IBS sum scores during the trial by allocation
group. The IBS sum score in the active period was 6.44
(1.81), in the placebo period 5.35 (1.77), and the correla-
tion between these was 0.66. The difference in IBS sum
score between active treatment and placebo was 1.09
(1.47). The resulting proportion of subjects with a score
difference of at least 2 in disfavour of active treatment was
27% (CI 9% to 44%), and the number needed to harm was
3.7 (CI 2.3 to 10.9).
L. plantarum was not detected in the faeces in any of
the subjects in the run-in period, in the washout period
(except for in one subject given active treatment in the
first period), nor in the placebo period. However, L.
plantarum was detected in all faecal samples at the end
of the active treatment period, indicating that the analy-
sis was targeting strain MF1298.
Compliance with intake of drugs was 95%. Two parti-
cipants did not return their unused drugs after the last
treatment period.
One participant had a short stay in hospital for cervi-
cobrachialgia during the washout period, two weeks
after the end of active treatment. There was no organic
explanation and she continued in the trial. Three minor
adverse events were noted.
Discussion
The study shows an unfavourable effect on symptoms in
subjects with IBS after intake of L. plantarum MF1298
compared to placebo. To our knowledge, similar unfa-
vourable effects of probiotics have not been reported in
subjects with IBS. Other studies with probiotics in sub-
jects with IBS show either no effect or a favourable
effect [6]. The divergent results could be related to dif-
ferent probiotic properties and health effects of the gen-
era, strains, and species in use. Quigley assumed the
possible superiority of Bifidobacterium spp for treatment
in IBS [13]. Bifidobacterium (B.) animalis DN-173010
increased stool frequency in subjects with constipation
at entry in a large study [14]. O’Mahony et al. compared
the symptomatic effect of L. salivarius UCC4331 and B.
infantis 35624 in subjects with IBS [15]. B. infantis
35624 induced a favourable effect on IBS symptoms. In
a second study by the same researchers, the beneficial
effect of B. infantis 35624 was confirmed [16]. Lactoba-
cilli have been evaluated in several trials with inconsis-
tent results, but no deleterious effects have been
reported. One trial of L. reuteri ATCC 55730 showed
no significant effect on gastrointestinal symptoms in
patients with IBS, while another trial also in patients
with IBS showed no effect of L. casei strain GG [17]. L.
casei strain GG in combination with other probiotics
showed a positive effect on IBS symptoms in one study
by Kajander [18]. Two trials with L. plantarum 299v
showed a reduction of abdominal pain and flatulence,
while a small crossover study found no effect on symp-
toms of IBS [19].
Reports of unfavourable effects of probiotics are rare
and probiotics have until recently been regarded as safe
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[6]. Untoward effects were reported in only three out of
185 human studies [20]. A strain of L. acidophilus
increased faecal protein catabolites in healthy volunteers
in one study, while Saccharomyces cerevisiae increased
disease activity in patients with stable Crohn’s disease in
one study, and in another study increased serum glucose
in healthy volunteers [20]. Sepsis has been reported in
some subjects using probiotics [21]. The most alarming
report was published in 2008, showing increased mortal-
ity of severe acute pancreatitis following treatment with
a multispecies probiotic preparation [22].
The doses of probiotics used for the treatment of IBS
in other trials vary from 2 × 108 to 2 × 1010 CFU per
day [7,15,19,23,24]. In a dose-finding study, the optimal
dose of B. infantis 35624 was 1 × 108 CFU which was
superior to placebo, 1 × 106 CFU and 1 × 1010 CFU.
Figure 1 Flow chart of the participants through the trial.
Table 1 Daily symptom scores and number of weeks with satisfactory relief of symptoms during the two treatment
periods.
Symptoms LpMF1298 Placebo Paired differences, mean (CI) Statistics
Number of weeks with satisfactory relief of symptoms 0.50 (0.89) 1.44 (1.26) -0.94 (-1.57 to -0.31) P = 0.006
Individual symptoms
Abdominal Pain/Discomfort 1.55 (0.57) 1.14 (0.55) 0.41 (0.09 to 0.73) P = 0.016
Stool frequency (normalised) 0.15 (0.18) 0.19 (0.21) -0.03 (-0.14 to 0.07) P = 0.48
Stool consistency (normalised) 0.86 (0.55) 0.61 (0.55) 0.25 (-0.12 to 0.61) P = 0.17
Urgency 1.54 (0.59) 1.12 (0.56) 0.42 (0.17 to 0.66) P = 0.002
Bloating 1.23 (0.59) 1.16 (0.68) 0.07 (-0.31 to 0.46) P = 0.69
Straining 0.51 (0.37) 0.58 (0.40) -0.07 (-0.17 to 0.03) P = 0.13
Incomplete bowel movement 0.59 (0.35) 0.54 (0.41) 0.05 (-0.06 to 0.17) P = 0.35
Sum symptoms
IBS sum score 6.44 (1.81) 5.35 (1.77) 1.09 (0.31 to 1.87) P = 0.010
Stool characteristics
Stool frequency 1.52 (0.68) 1.33 (0.58) 0.19 (-0.07 to 0.45) P = 0.15
Stool consistency 4.84 (1.51) 4.17 (1.31) 0.67 (0.20 to 1.13) P = 0.008
Diarrhoea (consistency + frequency) 6.36 (1.99) 5.50 (1.71) 0.86 (0.33 to 1.39) P = 0.004
The results are given as mean(SD).
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However, the 1 × 1010 CFU dose was associated with
significant formulation problems [16]. The only previous
study in humans with L. plantarum MF1298 is a study
of the survival and persistence of the strain in the gas-
trointestinal tract in 17 healthy volunteers. They were
given 6 × 109 CFU per day of L. plantarum MF1298
either as a freeze-dried preparation or present in 15 g
fermented sausage. No gastrointestinal symptoms or
other adverse events were spontaneously reported, but
such symptoms were not systematically recorded [10].
The dose of 1 × 1010 CFU L. plantarum MF1298
selected for this study was in the same order as the
doses used in other studies with lactobacilli [20]. Despite
the lack of evidence for a reduced or detrimental effect
of high doses, we cannot exclude that a too high dose
might have contributed to the unfavourable outcome of
this study.
It has been proposed that the most potent probiotics
may have increased pathogenicity [21]. The multispecies
probiotic preparation used in the study of acute, severe
pancreatitis where mortality was increased, was com-
posed of six strains [22]. These strains, selected from 69
different probiotic bacteria, had better probiotic proper-
ties in combination than the individual components. L.
plantarum MF1298 had the best in vitro probiotic prop-
erties of 22 strains [8-10]. The probiotic with the best
probiotic properties as determined in vitro is not
Table 2 Number of subjects with satisfactory relief of symptoms for 0, 1, 2, and 3 weeks in the two treatment periods.
Number of subjects with satisfactory relief of symptoms for 0, 1, 2, and 3 weeks
in the placebo period
Total no. of subjects
0 week 1 week 2 weeks 3 weeks
Number of subjects 0 week 4 4 1 2 11
with satisfactory relief 1 week 1 0 0 2 3
of symptoms for 0, 1, 2, and
3 weeks
2 weeks 0 0 1 0 1
in the LpMF1298 period 3 weeks 0 0 0 1 1
Total no. of subjects 5 4 2 5 16
The difference in favor of placebo was statistically significant (P = 0.012).
Figure 2 IBS sum score during the trial by allocation group. The results are given as mean with SEM.
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necessarily the best one to “confer a health benefit on
the host”.
The possibility of contamination of capsules by patho-
gens was excluded in our study, but the presence of
endotoxins in the L. plantarum MF1298 and placebo
preparations was not checked. This is, however, unlikely
to be the reason for the unfavourable effect, because the
company providing the capsules is a reliable producer of
food supplements.
The serious adverse event and three minor adverse
events reported were judged to be unrelated to the
treatment.
Strengths and weaknesses
Probably due to the heterogeneity of the sample in
terms of bowel habit predominance, we cannot point to
aggravation of a specific symptom. But all outcomes,
both the primary outcome (treatment preference) and
the secondary outcomes (number of weeks with satisfac-
tory relief of symptoms and IBS sum score), show the
same unfavourable direction for active treatment. This
strengthens the internal validity, but a type I error can-
not be excluded.
With an IBS sum score difference of 2 chosen as clini-
cally significant, the number needed to harm was 3.7. A
2-point difference on a scale with a range of 15 means
13%, and a change of 10% is often regarded as signifi-
cant on such scales. However, the IBS sum score was
not validated for responsiveness and clinically significant
differences. Considering that the mean IBS sum score in
the run-in period was 5.97, the score difference of 2
chosen as clinically significant might be rather high.
In this study the mean age of subjects was 50 years
and the proportions of subjects with diarrhoea predomi-
nant, constipation predominant, and alternating IBS
were 38%, 6%, and 56%, respectively. In corresponding
studies the participants were younger and the propor-
tions of subjects in the subgroups were more balanced
[1,25]. The older age and the somewhat different distri-
bution of subgroups in our study raise the question of
external validity. A beneficial effect in younger subjects,
in subjects with more or less symptoms compared with
our participants, in subgroups of subjects (such as con-
stipation predominant), or in populations with other
dietary habits and gut microflora cannot be excluded.
Furthermore, a longer period of intervention would have
strengthened the internal validity, but increased the
drop-out rates.
The advantage of the crossover design used in this
study is the increase in power of within-participant
comparisons, and thus its requirement for fewer partici-
pants. For ethical reasons, the number of participants
and the study period should be reduced as much as pos-
sible in a phase II study like this one. The design is
fitted for stable chronic diseases [26]. Although IBS is a
fluctuating disease, Figure 2 shows that the prerequisites
for the use of this design were fulfilled. The IBS sum
scores in the two periods were not significantly different.
The detection of L. plantarum MF1298 in one faecal
sample at the end of the washout period indicates that
the washout period was too short in this subject. How-
ever, because the amount of L. plantarum MF1298
detected was small and the recording of symptoms took
place in the last week of the three-week treatment per-
iod, the possibility for a carryover effect is negligible. In
summary, the crossover design turned out to be
appropriate.
Conclusions
The results from our study contribute to focus on the
risks of using strains with probiotic properties without
scientific evaluation. Not all strains with in vitro demon-
strated probiotic properties actually “confer a health
benefit on the host”, and their use may even be asso-
ciated with unfavourable effects. L. plantarum MF1298
might be an unfavourable strain and this should stimu-
late basic research on the molecular basis of probiotic
properties.
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